Delcath Systems

Results: 7



#Item
1Food and Drug Administration Advisory Committee Member Acknowledgment of Disclosure of Financial Interests Name of Advisory Committee Temporary Voting Member: Wen-Jen Hwu, M.D., Ph.D. Committee: Oncologic Drugs Advisory

Food and Drug Administration Advisory Committee Member Acknowledgment of Disclosure of Financial Interests Name of Advisory Committee Temporary Voting Member: Wen-Jen Hwu, M.D., Ph.D. Committee: Oncologic Drugs Advisory

Add to Reading List

Source URL: www.fda.gov

Language: English
2DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993

Add to Reading List

Source URL: www.fda.gov

Language: English
3FDA Briefing Document Oncologic Drugs Advisory Committee Meeting May 2, 2013 NDA[removed] – 001 Melblez Kit Delcath Systems, Inc.

FDA Briefing Document Oncologic Drugs Advisory Committee Meeting May 2, 2013 NDA[removed] – 001 Melblez Kit Delcath Systems, Inc.

Add to Reading List

Source URL: www.fda.gov

Language: English
4Food and Drug Administration Advisory Committee Member Acknowledgment of Disclosure of Financial Interests Name of Advisory Committee Temporary Voting Member: Takami Sato, M.D., Ph.D. Committee: Oncologic Drugs Advisory

Food and Drug Administration Advisory Committee Member Acknowledgment of Disclosure of Financial Interests Name of Advisory Committee Temporary Voting Member: Takami Sato, M.D., Ph.D. Committee: Oncologic Drugs Advisory

Add to Reading List

Source URL: www.fda.gov

Language: English
5Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned James C. Yao, Diane Reidy Lagunes and Matthew H. Kulke The Oncologist published online April 24, 2013 Downloaded from http

Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned James C. Yao, Diane Reidy Lagunes and Matthew H. Kulke The Oncologist published online April 24, 2013 Downloaded from http

Add to Reading List

Source URL: www.carcinoid.org

Language: English - Date: 2013-04-30 13:14:03
6Clinical Practice Guideline

Clinical Practice Guideline

Add to Reading List

Source URL: www.albertahealthservices.ca

Language: English - Date: 2013-08-26 17:07:30
7Mirna Therapeutics Announces Interim Phase 1 Safety Data on Lead Product Candidate MRX34 at AACR Annual Meeting --MRX34 found to have manageable safety profile during initial dose-escalation phase of clinical trial in pa

Mirna Therapeutics Announces Interim Phase 1 Safety Data on Lead Product Candidate MRX34 at AACR Annual Meeting --MRX34 found to have manageable safety profile during initial dose-escalation phase of clinical trial in pa

Add to Reading List

Source URL: mirnarx.com

Language: English - Date: 2014-04-08 15:32:40